Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Clear Cell Renal Carcinoma (Ccrcc)”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05363631
What this trial is testing

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Who this might be right for
Clear Cell Renal Cell CarcinomaClear Cell Renal Cell Carcinoma Metastatic
Mohammed Milhem 55
Large-scale testing (Phase 3)Active Not RecruitingNCT07000149
What this trial is testing

Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Who this might be right for
Advanced Clear Cell Renal Cell Carcinoma
AstraZeneca 1,116
Testing effectiveness (Phase 2)Ended earlyNCT02771626
What this trial is testing

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Clear Cell Renal Cell Carcinoma (ccRCC)MelanomaNon-small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc 118
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,653
Early research (Phase 1)Ended earlyNCT05121948
What this trial is testing

HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Who this might be right for
Squamous Cell Carcinoma of Head and NeckColo-rectal CancerNon Small Cell Lung Cancer+3 more
HiberCell, Inc. 35
Testing effectiveness (Phase 2)Ended earlyNCT05935748
What this trial is testing

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Who this might be right for
ccRCCClear Cell Renal Cell CarcinomaKidney Cancer+18 more
NiKang Therapeutics, Inc. 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06964958
What this trial is testing

LASER - a Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaKidney Cancer
Dana-Farber Cancer Institute 24
Large-scale testing (Phase 3)Active Not RecruitingNCT04810078
What this trial is testing

Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Who this might be right for
Clear Cell Renal Cell Carcinoma
Bristol-Myers Squibb 681
Early research (Phase 1)Looking for participantsNCT05277051
What this trial is testing

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 158
Early research (Phase 1)Looking for participantsNCT07195682
What this trial is testing

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Who this might be right for
Renal Cell Carcinoma
Bristol-Myers Squibb 125
Early research (Phase 1)Ended earlyNCT06191796
What this trial is testing

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Who this might be right for
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Exelixis 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06245915
What this trial is testing

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Who this might be right for
Advanced/Metastatic Clear Cell Renal Cell CarcinomaRecurrence
Arsenal Biosciences, Inc. 37
Early research (Phase 1)Active Not RecruitingNCT04696731
What this trial is testing

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Allogene Therapeutics 120
Early research (Phase 1)Study completedNCT00944905
What this trial is testing

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
Renal Cell CarcinomaNon-hodgkin's Lymphoma
Bristol-Myers Squibb 46
Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+7 more
Exelixis 1,314
Large-scale testing (Phase 3)Not Yet RecruitingNCT07197580
What this trial is testing

Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Who this might be right for
ccRCCRenal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited 40
Large-scale testing (Phase 3)Active Not RecruitingNCT05899049
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 249
Early research (Phase 1)Active Not RecruitingNCT02974738
What this trial is testing

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Who this might be right for
Advanced Solid TumorsSolid TumorSolid Carcinoma+13 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 120
Testing effectiveness (Phase 2)Study completedNCT03680521
What this trial is testing

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
Mirati Therapeutics Inc. 25
Testing effectiveness (Phase 2)Looking for participantsNCT05665361
What this trial is testing

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Who this might be right for
Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI) 100
Load More Results